How heart cells contribute to heart problems caused by Doxorubicin chemotherapy
Cardiac fibroblast MHCII contribution to cardiac pathophysiology in Doxorubicin cardiomyopathy
['FUNDING_FELLOWSHIP'] · TUFTS UNIVERSITY BOSTON · NIH-10994472
This study is looking at how certain heart cells called cardiac fibroblasts might cause heart problems in cancer patients who have been treated with Doxorubicin, with the hope of finding ways to protect their hearts from damage.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | TUFTS UNIVERSITY BOSTON (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10994472 on ClinicalTrials.gov |
What this research studies
This research investigates how cardiac fibroblasts, a type of heart cell, contribute to heart issues in patients who have received Doxorubicin chemotherapy. The study focuses on understanding the role of these cells in inflammation and fibrosis, which are common complications leading to heart failure. By using a mouse model, researchers will explore how these fibroblasts interact with immune cells and how their behavior changes in response to Doxorubicin. The goal is to identify mechanisms that could potentially be targeted to prevent heart damage in cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are undergoing treatment with Doxorubicin and are at risk of developing heart complications.
Not a fit: Patients who have not received Doxorubicin or those with pre-existing heart conditions unrelated to chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing heart failure in cancer patients treated with Doxorubicin.
How similar studies have performed: Previous research has shown that targeting immune responses in heart disease can be beneficial, suggesting that this approach may also yield positive results.
Where this research is happening
BOSTON, UNITED STATES
- TUFTS UNIVERSITY BOSTON — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZAMBRANO, MARIA ANTONIA — TUFTS UNIVERSITY BOSTON
- Study coordinator: ZAMBRANO, MARIA ANTONIA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.